Literature DB >> 19482087

Tumor lymphatics.

Jonathan Sleeman1, Anja Schmid, Wilko Thiele.   

Abstract

In this article we survey more than three centuries of observation and research into tumor-associated lymphatic vessels, and their role in the metastatic spread of cancer. This historical overview documents how questions regarding tumor lymphatics have been central to concepts about the process of metastasis, and how this has subsequently influenced the clinical treatment of cancer. In turn, we show how analysis of the efficacy of these treatments has challenged long-standing notions regarding the tumor lymphatics. Starting with the discovery of VEGFR-3 and its ligands VEGF-C and VEGF-D, we also review how the rapid developments over the last 15 years in the molecular analysis of the lymphatic system and in particular lymphangiogenesis have contributed to this debate. Finally we speculate on how apparently paradoxical bodies of evidence regarding the role of tumor lymphatics in determining patterns of metastatic spread might be reconciled.

Entities:  

Mesh:

Year:  2009        PMID: 19482087     DOI: 10.1016/j.semcancer.2009.05.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  37 in total

Review 1.  The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications.

Authors:  Jonathan P Sleeman; Blake Cady; Klaus Pantel
Journal:  Clin Exp Metastasis       Date:  2012-06-06       Impact factor: 5.150

2.  Key architectural changes in tumor-negative lymph nodes from metastatic-free oral cancer patients are valuable prognostic factors.

Authors:  Marilena Vered; Ginette Schiby; Anna Schnaiderman-Shapiro; Ilya Novikov; Ibrahim O Bello; Tuula Salo; Aleksi Rytkönen; Joonas H Kauppila; Alex Dobriyan; Ran Yahalom; Shlomo Taicher; Dan Dayan
Journal:  Clin Exp Metastasis       Date:  2014-01-07       Impact factor: 5.150

3.  Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.

Authors:  Lei Huang; Odile David; Robert J Cabay; Klara Valyi-Nagy; Virgilia Macias; Rong Zhong; Barry Wenig; Lawrence Feldman; Ralph Weichselbaum; Michael T Spiotto
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

4.  RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer.

Authors:  Alberto Briganti; Giorgio Gandaglia; Nicola Fossati; Marco Moschini; Francesco Montorsi
Journal:  J Natl Cancer Inst       Date:  2015-07-23       Impact factor: 13.506

5.  PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.

Authors:  Pramila Ramani; Aimie Norton; Michelle S Somerville; Margaret T May
Journal:  J Neurooncol       Date:  2012-03-01       Impact factor: 4.130

Review 6.  The lymph node pre-metastatic niche.

Authors:  Jonathan P Sleeman
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

Review 7.  Lymphangiogenesis and hemangiogenesis: potential targets for therapy.

Authors:  Marlys H Witte; Michael T Dellinger; Donald M McDonald; S David Nathanson; Francesco M Boccardo; Corradino C C Campisi; Jonathan P Sleeman; Jeffrey E Gershenwald
Journal:  J Surg Oncol       Date:  2011-05-01       Impact factor: 3.454

Review 8.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

Review 9.  Lymphangiogenesis: a new player in cancer progression.

Authors:  Masayuki Nagahashi; Subramaniam Ramachandran; Omar M Rashid; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

10.  Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes.

Authors:  Shihong Li; Beth Goins; Brian A Hrycushko; William T Phillips; Ande Bao
Journal:  Mol Pharm       Date:  2012-08-23       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.